Effect of liraglutide on vascular inflammation in type-2 diabetes: A randomized, placebo-controlled, double-blind, parallel clinical PET/CT trial - The Liraflame Trial

Steno Diabetes Center Copenhagen0 个研究点目标入组 100 人2016年11月2日

概览

暂无简介。

注册库

who.int

开始日期

2016年11月2日

结束日期

待定

最后更新

5年前

研究类型

Interventional clinical trial of medicinal product

性别

All

发起方

•1\) Given written informed consent
•2\) Male or female patients \>50 years with type 2 diabetes (WHO criteria)
•3\) HbA1c \= 48 mmol/mol (6\.5 %)
•4\) eGFR \= 30 ml/min/1\.73 m2 (estimated by CKD\-epi formula)
•5\) Stable glucose\-lowering medication for at least 4 weeks before the baseline PET/CT (excluding oral glucocorticoids, calcineurin inhibitors, dipeptidyl peptidase 4 (DPP4\) inhibitors, glucagon like peptide\-1 agonists and other agents, which in the investigator’s opinion could interfere with the effect of liraglutide)
•6\) Stable/no treatment of hypercholesterolemia 4 weeks before baseline PET/CT
•7\) Must be able to communicate with the investigator and understand informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes

•1\) Type 1 diabetes mellitus
•2\) Chronic pancreatitis / previous acute pancreatitis
•3\) Known or suspected hypersensitivity to trial product(s) or related products
•4\) Treatment 90 days prior to screening with oral glucocorticoids, calcineurin inhibitors, dipeptidyl peptidase 4 (DPP4\) inhibitors, glucagon like peptide\-1 agonists and other agents, which in the investigator’s opinion could interfere with the effect of liraglutide
•5\) Cancer or any other clinically significant disorder, except for conditions associated with type 2 diabetes history, which in the investigators opinion could interfere with the results of the trial
•6\) Clinical signs of diabetic gastroparesis
•7\) Previous bowel resection
•8\) Impaired liver function (transaminases \> two times upper reference levels)
•9\) Inflammatory bowel disease
•10\) Weight \>150 kg